(secondQuint)Registry Protocol- Melphalan Percutaneous Hepatic Perfusion for the Treatment of Unresectable Hepatic Malignancy.

 Post Marketing study: The CHEMOSAT kit containing Gen 2 filters has been used to treat patients since April 2011.

 This registry study is designed to collect the treatment outcome in patients who receive this treatment and use experience of the CHEMOSAT Kits by healthcare professionals.

 The safety and efficacy data from patients treated in the commercial setting is important in updating the safety profile as well as the risk/benefit of the treatment.

 The resource utilization information is essential in planning treatment strategy for patients.

 This registry does not follow any pre-determined protocol with respect to diagnosis, treatment or follow-up of the patient.

 The data collected will be gathered exclusively from current medical practice at participating institutions.

.

 Registry Protocol- Melphalan Percutaneous Hepatic Perfusion for the Treatment of Unresectable Hepatic Malignancy@highlight

Collection of Safety, Efficacy and Resource Utilization Information in Patients Who Have Received Melphalan PHP with the Delcath Hepatic Delivery System for the Treatment of Unresectable Hepatic Malignancy